danirixin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 24780598 |
| CHEMBL ID | 3039531 |
| SCHEMBL ID | 1198688 |
| MeSH ID | M0585895 |
| Synonym |
|---|
| CHEMBL3039531 |
| gsk1325756b |
| gsk-1325756b |
| gsk-1325756 |
| danirixin |
| 1-(4-chloro-2-hydroxy-3-(((3s)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea |
| 954126-98-8 |
| gsk1325756 |
| gsk 1325756 |
| unii-r318pgh5vp |
| danirixin [usan:inn] |
| r318pgh5vp , |
| n-(4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)phenyl)-n'-(3-fluoro-2-methylphenyl)urea |
| danirixin (usan/inn) |
| D10387 |
| (s)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea |
| danirixin [who-dd] |
| danirixin [usan] |
| danirixin [inn] |
| SCHEMBL1198688 |
| 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea |
| gtpl8500 |
| HY-19768 |
| CS-5465 |
| EX-A1178 |
| AKOS030527036 |
| mfcd27987922 |
| danirixin (gsk1325756) |
| DB11922 |
| Q27076980 |
| S6620 |
| urea, n-[4-chloro-2-hydroxy-3-[(3s)-3-piperidinylsulfonyl]phenyl]-n'-(3-fluoro-2-methylphenyl)- |
| AC-36168 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " All subjects also received omeprazole 20 mg each morning beginning 4 days prior to the first treatment period and continuing through danirixin dosing in the final treatment period." | ( The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Ambery, CL; Bloomer, JC; Connolly, P; Lazaar, AL; Miller, BE; Mistry, S; Sanderson, D; Shreeves, T; Smart, K; Smith, R, 2014) | 0.63 |
| " Dosed with normal/high fat food the selected formulation showed comparable exposure and a modest increase in DNX systemic PK was observed with PPI dependent on meal type." | ( Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK. Ambery, C; Bloomer, JC; Butler, JM; Charles, SJ; D'Amico, D; Donald, A; Hingle, MI; Lloyd, RS; Miller, B; Paul, A; Tal-Singer, R; Zhu, X, 2020) | 0.56 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0010 | 2.0227 | 10.0000 | AID1341911 |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 15.0025 | 0.0000 | 0.3029 | 6.0130 | AID1341912; AID1341914 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | C-X-C chemokine receptor type 1 | Homo sapiens (human) |
| secretory granule membrane | C-X-C chemokine receptor type 1 | Homo sapiens (human) |
| external side of plasma membrane | C-X-C chemokine receptor type 1 | Homo sapiens (human) |
| nucleoplasm | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| plasma membrane | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| cell surface | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| microtubule cytoskeleton | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| membrane | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| secretory granule membrane | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| mast cell granule | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| mitotic spindle | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| external side of plasma membrane | C-X-C chemokine receptor type 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346826 | Human CXCR2 (Chemokine receptors) | 2015 | BMC pharmacology & toxicology, Jun-20, Volume: 16 | The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (66.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||